The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Tremelimumab, durvalumab, and lenvatinib plus TACE in unresectable eeHCC
Stephen Lam Chan, MD, FRCP, Chinese University of Hong Kong, Hong Kong, China, shares efficacy and safety findings from EMERALD-3 (NCT05301842), a Phase III trial assessing tremelimumab plus durvalumab, with or without lenvatinib, in combination with transarterial chemoembolization (TACE) for patients with unresectable, embolization-eligible hepatocellular carcinoma (eeHCC). The study showed a statistically significant improvement in progression-free survival with the triplet regimen compared to TACE alone, along with a favorable trend in overall survival, highlighting this combination as a potential new therapeutic approach for eeHCC. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So EMERALD-3 is a clinical trial comparing three regimens in patients with embolization-eligible HCC. The first arm are those patients combining the TACE and the Sorafenib plus Lenvatinib. And the second arm, Arm B, those patients will combine Sorafenib together with the TACE, and the third arm is only TACE alone. So the primary endpoint was progression-free survival, according to response rate, and also there are some other standard secondary endpoints on efficacy and toxicity...
So EMERALD-3 is a clinical trial comparing three regimens in patients with embolization-eligible HCC. The first arm are those patients combining the TACE and the Sorafenib plus Lenvatinib. And the second arm, Arm B, those patients will combine Sorafenib together with the TACE, and the third arm is only TACE alone. So the primary endpoint was progression-free survival, according to response rate, and also there are some other standard secondary endpoints on efficacy and toxicity. The key results show that Arm A is better than Arm C in terms of the median progression-free survival with a hazard ratio around 0.7. So this study is considered a positive study.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
